Precision Medicine will need to get out of the pharma silo that is based on symptoms


Welcome to the digital era of biology (and to this modest blog I started in early 2005).

To cure many diseases, like cancer or cystic fibrosis, we will need to target genes (mutations, for ex.), not organs! I am convinced that the future of replacement medicine (organ transplant) is genomics (the science of the human genome). In 10 years we will be replacing (modifying) genes; not organs!


Anticipating the $100 genome era and the P4™ medicine revolution. P4 Medicine (Predictive, Personalized, Preventive, & Participatory): Catalyzing a Revolution from Reactive to Proactive Medicine.


After low-cost airlines (Ryanair, Easyjet ...) comes "low-cost" participatory medicine. Some of my readers have recently christened this long-lasting, clumsy attempt at e-writing of mine "THE LOW-COSTE INNOVATION BLOG". I am an
early adopter of scientific MOOCs. My name's Catherine Coste. I've earned myself four MIT digital diplomas: 7.00x, 7.28x1, 7.28.x2 and 7QBWx. Instructor of 7.00x: Eric Lander PhD.

Upcoming books: Airpocalypse, a medical thriller (action taking place in Beijing) 2017; Jesus CRISPR Superstar, a sci-fi -- French title: La Passion du CRISPR (2018).

I love Genomics. Would you rather donate your data, or... your vital organs?

Audio files on this blog are Windows files ; if you have a Mac, you might want to use VLC (http://www.videolan.org) to read them.

Concernant les fichiers son ou audio (audio files) sur ce blog : ce sont des fichiers Windows ; pour les lire sur Mac, il faut les ouvrir avec VLC (http://www.videolan.org).


Entrée en bourse de Nanobiotics

Soigner le cancer grâce aux nanotechnologies ? Une réalité, qui se concrétise, alors que la société franco-américaine Nanobiotics a réussi son entrée en bourse aujourd'hui ... Cette forme de thérapie innovante est compatible avec les traitements actuels (radiothérapie), ce qui plaît tant aux investisseurs. Des partenariats avec l'Asie (Chine) sont en cours de discussion ...La cotation débute aujourd'hui au NYSE Euronext à 6 EUR l'action ...(Source)

"Nanobiotics develops anti-cancer therapeutic approaches which are compatible with current practices. The company was founded in 2003 and is based in France." (Source).

1 commentaire:

Catherine a dit…

Cotation débute aujourd'hui au NYSE Euronext à 6 EUR l'action ...